Sign In
Buy ACIU
$2.50
+0.100 (+4.17%)
At Close: Jun 22, 2026
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease
07:00am, Thursday, 11'th Jun 2026
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of P
AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
10:56am, Wednesday, 03'rd Jun 2026
AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a t
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
07:00am, Friday, 22'nd May 2026
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Thursday, 14'th May 2026
AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
07:00am, Tuesday, 12'th May 2026
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appo
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates
09:30am, Thursday, 30'th Apr 2026
AC Immune (ACIU) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.
AC Immune First Quarter 2026 Financial and Corporate Updates
07:05am, Thursday, 30'th Apr 2026
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteer
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
07:00am, Thursday, 30'th Apr 2026
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
11:31am, Thursday, 09'th Apr 2026
AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
10:40am, Thursday, 09'th Apr 2026
Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.
Why AC Immune Stock Zoomed Almost 15% Higher Today
04:54pm, Tuesday, 07'th Apr 2026
This will help fund the biotech's development of a unique treatment for neurodegenerative diseases like Alzheimer's. The company could earn more than $2.1 billion if this work is successful.
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
07:00am, Tuesday, 07'th Apr 2026
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and signific
AC Immune (ACIU) Upgraded to Buy: Here's Why
01:00pm, Wednesday, 18'th Mar 2026
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year?
10:40am, Wednesday, 18'th Mar 2026
Here is how AC Immune (ACIU) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
